NCT01934738View on ClinicalTrials.gov

A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)

PHASE1CompletedINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Healthy

Interventions

DRUG

PF-06273340

Tablets, 100 mg TID, 14 days

DRUG

Placebo

Tablets, TID, 14 days

DRUG

PF-06273340

Tablets, to be decided dose, TID or titration, 14 days

DRUG

Placebo

Tablets, TID or titration, 14 days

DRUG

PF-06273340

Tablets, to be decided dose, TID or titration, 14 days

DRUG

Placebo

Tablets, TID or titration, 14 days

DRUG

PF-06273340

Tablets, to be decided dose, TID or titration, 14 days

DRUG

Placebo

Tablets, TID or titration, 14 days

DRUG

PF-06273340

Tablets, to be decided dose, TID or titration, 14 days

DRUG

Placebo

Tablets, TID or titration, 14 days

DRUG

PF-06273340

Tablets, to be decided dose, TID or titration, 14 days

DRUG

Placebo

Tablets, TID or titration, 14 days

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY